NB4168
Asset
Nicotinamide riboside-derived small molecule boosting NAD+ levels
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- NAD+ metabolism
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Ataxia telangiectasia
Preclinical, investors.niagenbioscience.com, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors1
- Aging relevance2
Every asset’s record: target, stage, trials and the evidence behind it.